Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes
Approximately 90% of patients with myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez)
Myelodysplastic Syndromes (MDS)
Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management
Disease overview: The myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN
Therapy-related myelodysplastic syndromes in the genomics era
Therapy-related myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorder
Raising the bar for lower-risk myelodysplastic syndromes
Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone
Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment
Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone
Health-Related Quality of Life and Vulnerability among People with Myelodysplastic Syndromes: A US National Study
Health-related quality of life (HRQoL) and vulnerability are variably affected in patients with myelodysplastic syndromes myelodysplastic syndrom
Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes
Lower risk myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders whe
The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances
The myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the